Hormonal
GLP-1RAs reduce emotional eating in the short term (3-6 months) by modulating reward processing, but this effect may not be long-lasting (12 months) and does not address underlying emotion regulation deficits.
GLP-1RAs like semaglutide can help reduce emotional eating for the first 3-6 months by changing how your brain responds to food rewards. However, this effect may fade after a year, and the medication does not fix the underlying emotional regulation skills. For lasting results, combine GLP-1RA treatment with emotion regulation therapies like CBT or DBT.
Research suggests that GLP-1RAs reduce emotional eating in the short term. Individuals with higher weight experienced a significant decrease in emotional eating frequency after three month [58] and six months [59] of semaglutide treatment.
Why this rating
Based on observational studies and some RCTs, but long-term data is limited and shows regression to baseline.
Source
Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
Isabel Krug et al. · Nutrients · 2025
DOI 10.3390/nu17233735
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.Good
- GLP-1RAs may pose theoretical risks for individuals with restrictive eating disorders (e.g., Anorexia Nervosa) or high perfectionism, as appetite suppression can mask or reinforce rigid control and compensatory behaviors.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →